Wells Fargo Keeps Equal-Weight Rating on United Therapeutics, Increases Price Target to $423
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Source: Benzinga
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies to improve their trading outcomes.
Market Intelligence: Benzinga Pro is marketed as the source for the fastest and most accurate stock market intelligence available.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UTHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 534.50 USD with a low forecast of 423.00 USD and a high forecast of 645.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 467.300
Low
423.00
Averages
534.50
High
645.00
Current: 467.300
Low
423.00
Averages
534.50
High
645.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
United Therapeutics Reports Positive Phase 1 Results for MiroliverELAP
- Clinical Trial Success: In a Phase 1 study for acute liver failure, five patients treated with miroliverELAP for at least 44 hours met the survival endpoint, demonstrating the product's potential to provide critical liver support in dire situations.
- Safety Assessment Positive: No unexpected serious adverse events were reported during a subsequent 32-day follow-up, indicating the safety of miroliverELAP in clinical applications and laying the groundwork for future commercialization.
- Future Research Plans: Full study results are expected to be published in the second half of 2026, further validating the efficacy and safety of miroliverELAP, which could drive its market adoption.
- Stable Stock Performance: United Therapeutics' stock has increased approximately 26.89% over the past 12 months, currently trading at $471, reflecting relatively strong market performance despite facing some technical pressure in the short term.
Continue Reading
United Therapeutics Upgraded to Overweight with Price Target of $535.73
- Rating Upgrade: United Therapeutics (UTHR) has received an upgrade to an overweight rating, reflecting analysts' optimistic expectations for its future performance, which may attract more investor attention.
- Price Target Set: Analysts have set a price target of $535.73, indicating confidence in the company's growth potential, which could drive the stock price towards this target.
- Market Reaction: The upgrade in rating and price target may enhance market confidence in United Therapeutics, potentially increasing the liquidity and attractiveness of its stock.
- Investor Strategy: By raising the rating and price target, analysts may aim to guide investors to reassess the investment value of United Therapeutics, thereby enhancing its competitiveness in the biopharmaceutical sector.
Continue Reading